THE ARISING · Longevity & Healthspan
Weight Training Reduced Lean Tissue Loss on Tirzepatide
Losing more than 20 kilograms on tirzepatide also means losing lean tissue, and a new trial shows that lifting weights three times a week reduced that loss and turned a fall in strength into a gain.
The study, published in Nature Medicine, was a randomised controlled trial of 120 adults with overweight or obesity. All were treated with tirzepatide, a weight-loss drug sold as Mounjaro. Half were randomly assigned to resistance exercise three times a week for 40 weeks. The other half carried on with usual activities. Adherence to the exercise was 91%, and most participants tolerated increases in the drug dose up to 15 mg weekly.
Weight loss was nearly identical. The drug-only group lost 22.61 kg and the exercise group lost 22.28 kg. Fat loss was also similar, at 17.19 kg and 17.98 kg.
The difference showed up in lean soft tissue, which includes muscle, organs, skin and body water but excludes bone mineral. The drug-only group lost 4.67 kg of it. The exercise group lost 3.57 kg, a reported between-group difference of 1.09 kg (95% confidence interval 0.43 to 1.75 kg). That is about 24% less lean tissue lost, calculated from the rounded group averages. Loss of lean mass in the arms and legs was also smaller with exercise: 2.92 kg against 3.55 kg.
Strength moved in opposite directions. With tirzepatide alone, bench press fell by 4.09 kg, lat pulldown by 4.42 kg and knee extension by 4.42 kg. With exercise added, they rose by 4.68 kg, 8.58 kg and 5.88 kg. The university's coverage puts the change at about 10% up for the trained group and 10% down for the others.
Participants were aged 50 to 70, according to the university's coverage, and did not have type 2 diabetes. Lead investigator Danny Green said loss of lean mass "is an inevitable part of weight loss by any method". "We now know that muscle loss can be reduced and strength increased when regular resistance training is used alongside tirzepatide treatment," he said. He argues resistance exercise should be part of the prescription for people on weight-loss drugs.
Green also said the goal should be better health and function, not just a lower number on the scales. In theory, he said, that should translate to a longer healthspan, meaning more years lived independent and free of chronic disease. The trial itself measured body composition and strength, not years of healthy life.
The university says the drug's manufacturer supplied tirzepatide free but had no part in the design, running or evaluation of the trial.
Next, watch for longer follow-up that shows whether the muscle and strength preserved during weight loss translate into healthier years, as Green expects.